Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauren B Banks

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future OutlookLauren B Banks, Sandra P D'Angelo
American Journal of Clinical Dermatology|February 7, 2020
When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?Lauren B Banks, Ryan J Sullivan
JBJS Reviews|December 20, 2023
Team Approach: Extremity Soft Tissue SarcomaCarol D Morris, Lauren B Banks, Valerie A Fitzhugh, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Akt2 deficiency impairs Th17 differentiation, augments Th2 differentiation, and alters the peripheral response to immunizationLauren B Banks, Tammarah Sklarz, Mercy Gohil, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 19, 2017
The Loss of TET2 Promotes CD8<sup>+</sup> T Cell Memory DifferentiationShannon A Carty, Mercy Gohil, Lauren B Banks, et al.
Cancer Medicine|June 21, 2026
Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II TrialsAdel Shahnam, Kristen DiConza, Simran Jasnani, et al.
Nature Immunology|May 7, 2013
Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathwaysJiyeon S Kim, Tammarah Sklarz, Lauren B Banks, et al.
Journal for Immunotherapy of Cancer|September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapyBenjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.
Nature Medicine|April 28, 2022
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CASmita S Chandran, Jiaqi Ma, Martin G Klatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future OutlookLauren B Banks, Sandra P D'Angelo
American Journal of Clinical Dermatology|February 7, 2020
When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?Lauren B Banks, Ryan J Sullivan
JBJS Reviews|December 20, 2023
Team Approach: Extremity Soft Tissue SarcomaCarol D Morris, Lauren B Banks, Valerie A Fitzhugh, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Akt2 deficiency impairs Th17 differentiation, augments Th2 differentiation, and alters the peripheral response to immunizationLauren B Banks, Tammarah Sklarz, Mercy Gohil, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 19, 2017
The Loss of TET2 Promotes CD8<sup>+</sup> T Cell Memory DifferentiationShannon A Carty, Mercy Gohil, Lauren B Banks, et al.
Cancer Medicine|June 21, 2026
Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II TrialsAdel Shahnam, Kristen DiConza, Simran Jasnani, et al.
Nature Immunology|May 7, 2013
Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathwaysJiyeon S Kim, Tammarah Sklarz, Lauren B Banks, et al.
Journal for Immunotherapy of Cancer|September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapyBenjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.
Nature Medicine|April 28, 2022
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CASmita S Chandran, Jiaqi Ma, Martin G Klatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
Pageof 2